• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

A Bad Case of Bromhidrosis in a Teenage Girl

News
Slideshow

The young woman's foot odor is accompanied by physical findings on the plantar surfaces. What's your Dx? Rx?

A 17-year-old girl sees you after her mother threatens to fumigate the young woman's bedroom. The problem is foot odor that you can barely tolerate when you enter the exam room. There are physical clues to the underlying problem as well as the pungent air. Follow the case in the slides above.What's in your differential? Your diagnosis?  

Related Content
Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults / image credit ©Waldenmarus/stock.adobe.com

Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults

Grace Halsey
October 2nd 2025
Article

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
August 25th 2025
Podcast

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care / image credit ©designua/stock.adobe.com

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care

Patient Care Editorial Staff
September 24th 2025
Article

Patient Care tapped the rich trove of research and expert perspective from the 2025 Revolutionizing Atopic Dermatitis meeting to create a snapshot of the AD care of the future.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group / image credit ©Waldenmarus/stock.adobe.com

FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group

Grace Halsey
September 19th 2025
Article

Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.

Temtokibart Shows Promise in Phase 2b Trials in Adults With Moderate-to-Severe Atopic Dermatitis / image courtesy of Skin Health Institute

Temtokibart Shows Efficacy and Strong Biomarker Response in Phase 2b Trial for Atopic Dermatitis

Grace Halsey
September 18th 2025
Article

The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.

© 2025 MJH Life Sciences

All rights reserved.